Apogee Therapeutics (APGE) Accounts Payables (2022 - 2026)

Apogee Therapeutics (APGE) has 5 years of Accounts Payables data on file, last reported at $1.2 million in Q1 2026.

• On a quarterly basis, Accounts Payables fell 49.41% year-over-year to $1.2 million in Q1 2026; TTM through Mar 2026 was $1.2 million, a 49.41% decrease from a year earlier, with the FY2025 full-year figure at $1.2 million, up 14.01% from the prior year.
• Accounts Payables for Q1 2026 stood at $1.2 million, up from $1.2 million in the prior quarter.
• Over the last five years, Accounts Payables for APGE reached as high as $11.1 million in Q2 2023 and fell as low as $376000.0 in Q3 2025.
• Historically, Accounts Payables has averaged $3.0 million across 5 years, with a median of $2.1 million in 2023.
• Across the five-year window, Accounts Payables jumped 412.68% in 2023 and tumbled 83.03% in 2025, its largest moves.
• Year by year, Accounts Payables stood at $418000.0 in 2022, then soared by 412.68% to $2.1 million in 2023, then sank by 50.02% to $1.1 million in 2024, then gained by 14.01% to $1.2 million in 2025, then rose by 1.31% to $1.2 million in 2026.
• Per Business Quant data, the three most recent Accounts Payables figures were $1.2 million in Q1 2026, $1.2 million in Q4 2025, and $376000.0 in Q3 2025.